library.onepin.app/t4-levothyroxine-synthroid Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Metabolic

Metabolic Thyroid Hormone (storage form) Controlled substance Prescription drug

T4 (Levothyroxine / Synthroid)

T4 · Synthroid · Levothroid · Levothyroxine Sodium

Thyroid Hormone (storage form)Synthetic thyroxineFDA-ApprovedWADA Not Prohibited (monitored)

Levothyroxine sodium (T4) is the synthetic form of thyroxine, the primary storage hormone produced by the thyroid gland. It is converted peripherally in the liver, kidneys, and other tissues to the biologically active form, triiodothyronine (T3), via the deiodinase enzymes. Levothyroxine is one of the most prescribed medications in the world and is the first-line treatment for primary hypothyroidism. It is FDA-approved under brand names including Synthroid, Levoxyl, Tirosint, Euthyrox, and Unithroid.

Quick Start
Route
Oral
Start low
25mcg
Frequency
1x daily
Timing
Take on empty stomach, 30-60 minutes before food / calcium / iron / antacids

Take in the morning on an empty stomach, 30-60 minutes before breakfast, calcium, iron supplements, or antacids, as these dramatically reduce absorption. Starting dose is typically 25-50 mcg/day for adults without cardiac disease, with 12.5 mcg increments every 4-6 weeks based on TSH response. Do not expect to feel a change for the first 1-2 weeks - T4 takes 4-6 weeks to reach new steady state.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
25mcg · Oral · 1x daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
25mcg
1x daily
Standard
Baseline Thyroid Replacement
50-100 mcg · Oral · Daily
human study · Jonklaas et al. 2014 (Thyroid)
50-100 mcg
Daily
01

How it works

Levothyroxine is identical to endogenous T4. It serves as the circulating storage form of thyroid hormone and is converted to the active T3 by peripheral deiodinase enzymes (predominantly type 1 and type 2 deiodinases) in the liver, kidneys, pituitary, thyroid, skeletal muscle, and brain. The resulting T3 binds nuclear thyroid hormone receptors (TR-alpha and TR-beta), regulating transcription of genes controlling basal metabolic rate, oxygen consumption, protein turnover, carbohydrate and lipid metabolism, and thermogenesis.

Levothyroxine is identical to endogenous T4. It serves as the circulating storage form of thyroid hormone and is converted to the active T3 by peripheral deiodinase enzymes (predominantly type 1 and type 2 deiodinases) in the liver, kidneys, pituitary, thyroid, skeletal muscle, and brain. The resulting T3 binds nuclear thyroid hormone receptors (TR-alpha and TR-beta), regulating transcription of genes controlling basal metabolic rate, oxygen consumption, protein turnover, carbohydrate and lipid metabolism, and thermogenesis.

The long plasma half-life (approximately 7 days) reflects high-affinity binding to thyroxine-binding globulin (TBG), transthyretin, and albumin. This binding pool buffers daily fluctuations and produces the stable circulating levels that make T4 the preferred replacement hormone. A dose change requires 4-6 weeks (five half-lives) to reach new steady state, which is why TSH should not be re-measured earlier than six weeks after a dose adjustment.

Food, calcium, iron, aluminum-containing antacids, bile acid sequestrants, and soy proteins reduce absorption significantly - hence the 30-60 minute empty-stomach dosing convention. Peripheral T4-to-T3 conversion is reduced by glucocorticoids, propranolol at high doses, amiodarone, and certain illnesses (for example severe systemic illness, 'low T3 syndrome').

02

What to expect

Early
Days 1–7

First 1-2 weeks: minimal perceptible change. Plasma T4 is climbing toward new steady state but peripheral T3 levels lag.

Mid
Weeks 2–4

Weeks 3-6: clinical improvement in fatigue, cold intolerance, constipation, dry skin, and mood. TSH begins to drop. Recheck TSH at week 6 and adjust dose accordingly.

Later
Weeks 4–12

Months 2-4: full steady state and symptomatic benefit. Subsequent dose changes take another 6 weeks to equilibrate. Maintenance dosing is typically lifelong in primary hypothyroidism.

03

Evidence

HumanStrong
AnimalPresent
In-vitroPresent
2018Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy · Hennessey JV, Espaillat R, International Journal of Clinical Practice ↗review
2007Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial · Razvi S, Ingoe L, Keeka G et al, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed
2024Effects of levothyroxine in subclinical hypothyroidism and heart failure with reduced ejection fraction: An open-label randomized trial · Wong A, Yu CM, Kim K et al, American Heart Journal ↗peer reviewed
2026Fasting vs. Non-Fasting, Dose-Adjusted Levothyroxine Ingestion In Hypothyroidism: A Randomized Clinical Trial · Cappelli C, Pirola I, Daffini L et al, Journal of Endocrinological Investigation ↗peer reviewed
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Keep separate

05

Side effects & safety

Commonly reported

  • Typically no side effects at correct replacement dose - T4 replaces a deficient hormone
  • Symptoms of overdose: tachycardia, palpitations, tremor, heat intolerance, insomnia, weight loss, diarrhea
  • Symptoms of underdose: fatigue, cold intolerance, constipation, dry skin, weight gain, brain fog
  • Transient hair shedding early in therapy is common and self-limiting

Less common & notes

  • Chronic over-replacement increases the risk of atrial fibrillation (especially in older patients) and accelerates bone turnover (osteoporosis risk).
  • Rare allergic reactions to tablet excipients (dyes, lactose) - hypoallergenic formulations like Tirosint are available.
  • Angina or myocardial ischemia can be precipitated by starting too high a dose in patients with underlying coronary disease - hence the lower 25 mcg starting dose in cardiac patients.
  • Pregnancy dose requirement increases ~30% - requires close TSH monitoring.
06

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~7 days (approximately 1 week)
Peak · Tmax
2-4 hours (absorption); days to weeks for clinical effect
Elimination
4-6 weeks to full steady state after dose change
Activity
7-10 days per dose - supports once daily dosing with stable blood levels

Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from light and moisture. Keep in original container. Shelf life typically 2-3 years from manufacture date. Moisture can degrade potency - do not transfer to humid pill organizers long-term. Keep out of reach of children.

07

Regulatory status

FDA-approved under brand names including Synthroid (AbbVie), Levoxyl (Pfizer), Tirosint (IBSA), Euthyrox (Merck KGaA), and Unithroid (Jerome Stevens). Generic levothyroxine is widely available. Prescription-only in the United States; not a controlled substance. Not prohibited by WADA - thyroid hormones are not on the current WADA prohibited list, though monitored in athletes. Internationally available under various brand names.

Put it to work

Calculate, log & track

Open T4 (Levothyroxine / Synthroid) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open T4 (Levothyroxine / Synthroid) in the app →

Go deeper

The guide & community

The complete T4 (Levothyroxine / Synthroid) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community